







CIN: L24231GJ1988PLC011652

#### November 15, 2025

To, **BSE Limited** 

Listing Compliance & Legal Regulatory Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai - 400 001

Stock Code: 543233

To,

National Stock Exchange of India Limited

Listing & Compliance

Exchange Plaza, Bandra-Kurla Complex,

Bandra East, Mumbai 400 051 Stock Symbol: CHEMCON

Dear Sir/Madam,

**Sub: Investor Presentation** 

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing obligations and Disclosure Requirements), Regulations, 2015, please find enclose herewith the "Investor Presentation" for November 2025.

The aforementioned presentation is also being uploaded on the Company's website at <a href="www.cscpl.com">www.cscpl.com</a>.

We request you to take the above on your records.

Thanking you, Yours faithfully,

For Chemcon Speciality Chemicals Limited

Shahilkumar Kapatel Company Secretary & Compliance Officer

Membership No.: A52211

Corporate Office: 9th Floor, Onyx Business Center, Akshar Chowk, Old Padra Road, Vadodara - 390 020. INDIA Tel.: +91 265 2981195/

2983754, Email: info@cscpl.com

Regd. Office : Block No. 355, Manjusar - Kunpad Road, Village: Manjusar, Taluka: Savli, Dist.: Vadodara - 391 775. INDIA

Tel.: +91 2667 264104



















**Chemcon Speciality Chemicals Limited Investor Presentation – November 2025** 

# Safe Harbor



This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Chemcon Speciality Chemicals Limited (the "Company")**, have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

# Q2 & H1 FY26 Performance Highlights



# Q2 FY26 Performance Highlights



"Overall business performance for the quarter and first half of the year began on a steady note, despite weak offtake from Pharma clients. The Company reported revenue of ₹53 crore for Q2FY26, a growth of 2% YoY, and ₹107 crore for H1FY26, reflecting a growth of 9% on YoY basis. Our Organic Chemicals segment delivered a resilient performance, supported by steady demand for HMDS, CMIC, 2-Bromo and Bromobenzene from pharmaceutical, agrochemical and aromatic customers. However, aggressive dumping in global markets continued to put pressure on the pricing of key products. The Inorganic Chemicals division remained impacted due to crude oil volatility, geopolitical uncertainties, and reduced oil drilling activity, leading to lower bromide volumes during the period.

On the strategic front, construction of our new units is progressing slowly and is expected to commence in the coming quarters with a new range of products. While some of our newly launched products are still in the early stages of market acceptance, we anticipate a gradual improvement as customer adoption improves.


In line with our efforts to diversify and de-risk the business, we have acquired the entire business of Shivam Petrochem Industries for ₹36 crore via a slump sale. The company is engaged in the manufacturing and distribution of bulk drugs, chemical intermediates, solvents, and other chemicals. This acquisition marks an important milestone in our growth journey, strengthens our product portfolio, and reinforces our confidence in achieving sustained growth in the coming quarters."

Mr. Kamal Aggarwal,

**Chairman & Managing Director** 

# Financial Highlights





# Financial Highlights





# Inorganic Growth – Acquired Shivam Petrochem Industries



#### Acquired Shivam Petrochem Industries for INR 36 crore through a slump sale

#### **Company Overview**


 Manufactures, processes, trades, and distributes bulk drugs, chemical intermediates, solvents, and other chemical products.

#### **Key Rationale**

- To accelerates growth by acquiring a business that strengthens the Company's core product portfolio
- To unlock cost efficiencies, operational improvements & shared resource advantages
- Adds technical know-how, product capabilities, and experienced talent
- Provides access to new markets, customers, and established relationships.

#### **Key Products**

- > Trityl Chloride (TTC)1-[(2-Chlorophenyl)(Diphenyl)
- Methyl] 1H-imidazolePara Toluene Sulfonyl Chloride (PTSCL)
- 2-Chlorotrityl Chloride (2CTC)
- Toluenesulfonylmethyl isocyanide (TosMIC)
- > 2-AcetylthiopheneThiophene-
- > 2-acetyl ChlorideThiophene-
- 2-carboxaldehydePyridine-4-carbaldehyde



Through Slump Sale Agreement, the Company acquired the **entire business** undertaking of M/s. Shivam Petrochem Industries (Partnership Firm, a related party) as a going concern for a lump sum consideration of ₹ 36.00 crore.

\*Subject to all necessary approvals

# **Profit & Loss Statement**



| Particulars (Rs. Crs)   | Q2 FY26 | Q2 FY25 | Y-o-Y | Q1 FY25 | Q-o-Q | H1 FY26 | H1 FY25 | Y-o-Y |
|-------------------------|---------|---------|-------|---------|-------|---------|---------|-------|
| Revenue from Operations | 53.7    | 52.6    | 2%    | 53.5    | 0%    | 107.2   | 98.1    | 9%    |
| Cost of Goods Sold      | 34.2    | 31.6    |       | 31.5    |       | 65.7    | 57.7    |       |
| Employee Cost           | 4.9     | 4.7     |       | 5.0     |       | 9.9     | 9.5     |       |
| Other Expenses          | 7.7     | 7.7     |       | 9.3     |       | 17.0    | 15.3    |       |
| EBITDA                  | 6.9     | 8.5     | -19%  | 7.7     | -12%  | 14.6    | 15.6    | -6%   |
| Other Income            | 3.9     | 3.5     |       | 3.7     |       | 7.6     | 7.3     |       |
| Depreciation            | 2.8     | 2.5     |       | 2.7     |       | 5.5     | 5.1     |       |
| EBIT                    | 8.0     | 9.5     |       | 8.7     |       | 16.7    | 17.8    |       |
| Finance Cost            | 0.1     | 0.9     |       | 0.3     |       | 0.4     | 1.9     |       |
| Profit before Tax       | 7.9     | 8.5     |       | 8.4     |       | 16.3    | 15.9    |       |
| Tax                     | 2.2     | 2.2     |       | 2.0     |       | 4.2     | 4.2     |       |
| PAT                     | 5.7     | 6.3     | -9%   | 6.4     | -10%  | 12.1    | 11.7    | 4%    |
| PAT Margin %            | 10.7%   | 12.0%   |       | 11.9%   |       | 11.3%   | 11.9%   |       |
| Basic EPS (in Rs.)      | 1.57    | 1.73    |       | 1.74    |       | 3.31    | 3.19    |       |

# Balance Sheet



| ASSETS (Rs. Crs)                 | Sep-25 | Mar-25 |
|----------------------------------|--------|--------|
| Non-Current Assets               |        |        |
| a) Property, Plant And Equipment | 144.2  | 148.7  |
| b) Capital Work in Progress      | 46.5   | 39.9   |
| c) Right Of Use Asset            | 0.0    | 0.0    |
| d) Intangible Assets             | 0.0    | 0.0    |
| e) Investments                   | 2.0    | 0.3    |
| f) Other Financial Assets        | 84.8   | 42.6   |
| g) Other Non-Current Assets      | 2.8    | 3.5    |
|                                  |        |        |
| Sub-Total - Non-Current Assets   | 280.4  | 234.9  |
|                                  |        |        |
| Current Assets                   |        |        |
| a) Inventories                   | 75.6   | 86.1   |
| b) Financial Assets              |        |        |
| i) Investments                   | 8.7    | 9.8    |
| ii) Trade Receivables            | 57.6   | 51.7   |
| iii) Cash And Cash Equivalents   | 19.0   | 7.1    |
| iv) Bank Balances                | 90.1   | 134.4  |
| v) Other Financial Assets        | 7.6    | 7.1    |
| c) Other Current Assets          | 8.7    | 22.6   |
| d) Current tax assets            | 0.0    | 0.2    |
| Sub-Total - Current Assets       | 267.4  | 319.0  |
| Total - Assets                   | 547.8  | 553.9  |

| EQUITY AND LIABILITIES (Rs. Crs)    | Sep-25 | Mar-25 |  |
|-------------------------------------|--------|--------|--|
| EQUITY AND LIABILITIES              |        |        |  |
| Equity                              |        |        |  |
| a) Equity Share Capital             | 36.6   | 36.6   |  |
| b) Other Equity                     | 476.1  | 464.0  |  |
| Total Equity                        | 512.7  | 500.7  |  |
| Liabilities                         |        |        |  |
| Non-Current Liabilities             |        |        |  |
| a) Financial Liabilities            |        |        |  |
| i) Borrowings                       | 0.1    | 0.2    |  |
| ii) Lease Liabilities               | 0.0    | 0.0    |  |
| iii) Other financial liabilities    | 0.0    | 0.0    |  |
| b) Non current Provisions           | 1.0    | 0.8    |  |
| c) Deferred Tax Liabilities (Net)   | 4.7    | 4.6    |  |
| Sub-Total - Non-Current Liabilities | 5.8    | 5.6    |  |
| Current Liabilities                 |        |        |  |
| a) Financial Liabilities            |        |        |  |
| i) Borrowing                        | 0.2    | 24.5   |  |
| ii) Trade Payables                  | 19.5   | 16.3   |  |
| iii) Other Financial Liabilities    | 7.3    | 4.2    |  |
| iv) Lease Liabilities               | 0.0    | 0.0    |  |
| b) Other Current Liabilities        | 1.9    | 2.4    |  |
| c) Short Term Provisions            | 0.4    | 0.3    |  |
| d) Current tax Liabilities          | 0.2    | 0.0    |  |
| Sub-Total - Current Liabilities     | 29.3   | 47.7   |  |
| Total - Equity And Liabilities      | 547.8  | 553.9  |  |

# **Company Overview**



# **Company Snapshot**



Incorporated in 1988

Manufacturer of Speciality Chemicals



Business Verticals: Organic Chemicals and Inorganic Chemicals

Manufacturing Facilities near Manjusar, Vadodara, Gujarat

9 Operational Plants, 6 Owned Warehouses















**Only Manufacturer of HMDS in India** 



**3rd Largest** Manufacturer of HMDS Worldwide



**Largest** Manufacturer of CMIC worldwide



Only Manufacturer of Zinc Bromide in India



**Largest** Manufacturer of Calcium Bromide in India

# **Evolution**



#### **FY89**

» Company was incorporated as Gujarat Quinone Private Limited

#### FY95-98

- » First sale of few chemical products
- Pyridine Hydrobromide
- Para Nitro Benzyl Bromide
- Methyl Iodide
- GA-1

#### FY01-03

- » Commenced HMDS Business in 2001
- Discontinued few products due to lower demand

#### **FY05**

- » First export shipment of HMDS
- » Amalgamation of Chemcon Engineers Private Limited with Gujarat Quinone Private Limited; name changed to "Chemcon Speciality Chemicals Private Limited"

#### FY14-16

- » First sale of CMIC
- » First sale of Calcium Bromide (Solution)
- » First sale of Zinc Bromide (Solution)

#### **FY17**

- » First sale of Calcium Bromide (Powder)
- » First sale of Sodium Bromide (Solution)



#### FY18

- » Increase in annual installed production capacity for
- CMIC from 600 to 1,200 MTPA;
- Oilwell Completion Chemicals from 7,200 to 14,400 MTPA



#### **FY19**

» Increase in annual installed production capacity for CMIC from 1,200 MTPA to 1,800 MTPA



- FY20-21
- » Increase in HMDS Capacity by commissioning of plant P7
- » Plant P2 commissioned with a capacity to manufacture ancillary product of HMDS



#### FY22-24

- » Increase in CMIC & TMCS Capacity by commissioning of plant P8
- » Increase in bromobenzene capacity by commissioning plant P-9



#### FY25


» Added new product, 2 Bromo with a capacity of 600 MTPA

#### **FY26**

Acquired Shivam
 Petrochem Industries
 through slump sale

# Global Market Presence







# Key Countries » United States of » Japan America » United Arab » Italy Emirates » South Korea » Russia » Germany » Spain » People's Republic of » Thailand China » Malaysia

Over Two Decades of • Manufacturing Experience in Chemicals • Exports



**Well Equipped to Seize Upcoming Opportunities** 

# Key Long-Term Relationships



**Organic Chemicals** 

**Inorganic Chemicals** 

















Shree Radha CC Gran Limited
Overseas Liability Company

Longstanding Clients



**Strong Base** 



New Product Development



New Customer Reach

Top 5 customers contribute ~30%

Top 10 customers contribute ~45%


Few customers age more than 2 decades with us Major customers have been with us for more than 5 years

Well equipped to retain market presence

Leading to increase in new product base and reach out to new customers

# Moving up the Value Chain





# **Key Certifications**



**Key Certificates** 







R&D

#### In-house laboratory to test

- » Raw materials procured
- » New Products & Innovation
- » Final products testing at the various stages of the manufacturing process
- » Well equipped with new instruments & machinery



#### **Environment**

#### **Complying All Environment Laws**

- » The Environment (Protection) Act, 1986
- » Water Prevention and Control of Pollution Act
- » Air Prevention and Control of Pollution Act, 1981
- » We are a zero-discharge company



# Product Overview



### **Product Portfolio**



#### **Organic Chemicals**

#### **HMDS**

- HMDS, an organosilicon compound, is a reagent and a precursor to bases that are popular in organic synthesis and organometallic chemistry
- HMDS is widely used in the pharmaceutical industry as a silylating agent in the process of manufacture of pharmaceutical drugs of the Penicillin group

#### **CMIC**

- CMIC is an antiviral drug intermediate product, which is a key intermediate for anti-AIDS and anti-hepatitis B drug Tenofovir
- The downstream product of CMIC, Tenofovir is a nucleotide antiviral drug developed by Gilead Corporation of the United States.

#### Bromobenzene

Bromobenzene, is a clear, colourless or pale-yellow liquid. It is manufactured through bromination of benzene in presence of iron and has form of heavy, mobile, colorless liquid having a pungent odor.

#### 2 Bromo (Di-Bromo Methane)

 Di- Bromo Methane is a colorless liquid primarily used as a solvent and as an intermediate in the production of various industrial chemicals, including those found in perfumes.

#### Oil Drilling & Fluids

End User Industry

**Key Products** 

**Pharmaceuticals & Others** 


**Pharmaceuticals** 

Agrochemicals & Aromatics

Domestic

FY21

#### Business Performance (Rs in cr)



# 13% 23% 35% 40% 25% 107 106 60 82 44 52 Export 31 37 62 35

FY23

23

FY22

#### **Inorganic Chemicals**

#### **Bromides**

- Oilwell Completion Chemicals are used to complete the well and is normally a salty solution made up of chlorides or bromides
- Company manufacture a range of inorganic bromides, namely: Calcium Bromide (solution and powder), Zinc Bromide (solution) & Sodium Bromide (solution and powder)

FY25

FY24

# Manufacturing Facilities



| Sr No | Product categories  | Key Products   | Installed Capacity<br>(MTPA) | Located at<br>Vadoda |
|-------|---------------------|--|------------------------------|----------------------|
| 1     |                     | HMDS, CMIC, Bromobenzene, 2 Bromo and other ancillary products | 11,400                       | 9 Opera              |
| 2     | Organic Chemicals   | Proposed P-10 unit   | Q4FY26e                      | 2 Proposed<br>unde   |
| 3     |                     | Proposed P-11 unit   | Q4FY26e                      | In-House R           |
| 4     | Inorganic Chemicals | Range of Inorganic Bromides                                    | 15,000                       | 6 Owned              |

sar near jarat

Units

ion Plant

boratory

nouses

# Located at Manjusar near Vadodara, Gujarat





# **Growth Drivers**



#### **Capacity Expansion**

We plan to add additional manufacturing capacity P10 unit and P11 unit. These additional capacity will manufacture organic chemicals

#### **Exploring New Applications**

» Plan to expand the new products to have diversified product portfolio with diversified client base

#### **Import Substitution**

» Aims to capitalize on the potential growth of Organic Chemicals in India and to substitute imports

#### **Cost Efficiencies**

» Ongoing improvement in cost-efficiencies in the production process through Process re-engineering for efficient raw material consumption and through economies of scale

# Way Forward



**Moderate Growth in** 

**Organic Chemicals** 



**Healthy Growth in** 

**Inorganic Chemicals** 



**Exploring Opportunities in** 

**New Products** 



**Leading to Long Term Sustainable Growth** 


**New Products, New Clients, New Applications, New Opportunities** 

# Financial Highlights



# **Financial Trends**





# Balance Sheet



| ASSETS (Rs. Crs)                 | Mar-25 | Mar-24 |  |
|----------------------------------|--------|--------|--|
| Non-Current Assets               |        |        |  |
| a) Property, Plant And Equipment | 148.7  | 146.5  |  |
| b) Capital Work in Progress      | 39.9   | 42.4   |  |
| c) Right Of Use Asset            | 0.0    | 0.0    |  |
| d) Intangible Assets             | 0.0    | 0.0    |  |
| e) Investments                   | 0.3    | 0.0    |  |
| f) Other Financial Assets        | 42.6   | 0.9    |  |
| g) Other Non-Current Assets      | 3.5    | 2.3    |  |
|                                  |        |        |  |
| Sub-Total - Non-Current Assets   | 234.9  | 192.1  |  |
|                                  |        |        |  |
| Current Assets                   |        |        |  |
| a) Inventories                   | 86.1   | 61.6   |  |
| b) Financial Assets              |        |        |  |
| i) Investments                   | 9.8    | 0.0    |  |
| ii) Trade Receivables            | 51.7   | 81.9   |  |
| iii) Cash And Cash Equivalents   | 7.1    | 7.1    |  |
| iv) Bank Balances                | 134.4  | 163.5  |  |
| v) Other Financial Assets        | 7.1    | 9.6    |  |
| c) Other Current Assets          | 22.6   | 21.8   |  |
| d) Current tax assets            | 0.2    | 7.7    |  |
| Sub-Total - Current Assets       | 319.0  | 353.2  |  |
| Total - Assets                   | 553.9  | 545.2  |  |

| EQUITY AND LIABILITIES14            | Mar-25 | Mar-24 |
|-------------------------------------|--------|--------|
| EQUITY AND LIABILITIES              |        |        |
| Equity                              |        |        |
| a) Equity Share Capital             | 36.6   | 36.6   |
| b) Other Equity                     | 464.0  | 439.8  |
| Total Equity                        | 500.7  | 476.4  |
| Liabilities                         |        |        |
| Non-Current Liabilities             |        |        |
| a) Financial Liabilities            |        |        |
| i) Borrowings                       | 0.2    | 0.4    |
| ii) Lease Liabilities               | 0.0    | 0.0    |
| iii) Other financial liabilities    | 0.0    | 0.0    |
| b) Non current Provisions           | 0.8    | 0.3    |
| c) Deferred Tax Liabilities (Net)   | 4.6    | 4.4    |
| Sub-Total - Non-Current Liabilities | 5.6    | 5.1    |
| Current Liabilities                 |        |        |
| a) Financial Liabilities            |        |        |
| i) Borrowing                        | 24.5   | 42.3   |
| ii) Trade Payables                  | 16.3   | 12.0   |
| iii) Other Financial Liabilities    | 4.2    | 5.5    |
| iv) Lease Liabilities               | 0.0    | 0.0    |
| b) Other Current Liabilities        | 2.4    | 3.6    |
| c) Short Term Provisions            | 0.3    | 0.2    |
| d) Current tax Liabilities          | 0.0    | 0.0    |
| Sub-Total - Current Liabilities     | 47.7   | 63.7   |
| Total - Equity And Liabilities      | 553.9  | 545.2  |

## **Thank You**





#### **Chemcon Speciality Chemicals Ltd.**

CIN - L24231GJ1988PLC011652

Mr. Rajesh Gandhi - CFO

Email – <u>rajesh@cscpl.com</u>

www.cscpl.com

## $SGA^{\underline{\tt Strategic\ Growth\ Advisors}}$

#### Strategic Growth Advisors Pvt. Ltd.

CIN - U74140MH2010PTC204285

Mr. Om Kanadia / Ms. Shaily Patwa

Email - om.kanadia@sgapl.net / shaily.p@sgapl.net

+91 8454951156 / +91 9819494608

www.sgapl.net

